TABLE 3.

Clinical isolates of Acinetobacter spp. identified by the ASPE assay, ITS sequencing, and antimicrobial susceptibility tests

Identified species	No. of clinical isolates identified by:		No. (%) of strains resistant toa:
	ASPE assay	ITS sequencing	CIP	IPM	MEM	SAM	ATM	GEN	CAZ	FEP
A. baumannii	56	56	53 (95)	18 (32)	33 (59)	30 (54)	53 (95)	52 (93)	54 (96)	38 (69)
Genospecies 3	13b	15	0	6 (40)	5 (33)	1 (7)	7 (50)	5 (33)	6 (40)	4 (27)
Genospecies 13TU	19c	17	0	2 (12)	4 (24)	1 (6)	6 (35)	5 (29)	3 (18)	1 (6)
Genospecies 10	1	1	0	1 (100)	1 (100)	0	1 (100)	0	1 (100)	1 (100)
Acinetobacter sp. strain ADP1	NAd	1	0	0	0	0	0	1 (100)	0	0
Other speciese	3	2	0	1 (50)	0	0	0	1 (50)	1 (50)	0

^aThe drug abbreviations and their MICs are the following: CIP, ciprofloxacin (≥4 mg/liter); IPM, imipenem (≥16 mg/liter); MEM, meropenem (≥16 mg/liter); SAM, ampicillin-sulbactam (≥16 mg/liter); ATM, aztreonam (≥32 mg/liter); GEN, gentamicin (≥32 mg/liter); CAZ, ceftazidime (≥32 mg/liter); and FEP, cefepime (≥32 mg/liter).

^bFive isolates yielded results that were discrepant from those determined by sequencing, with four isolates that were assigned to genospecies 3 by sequencing being assigned to genospecies 13TU by ASPE and one isolate with genospecies 3 and genospecies 13TU signals concurrently.

^cFour discrepant isolates, with three isolates that were assigned to genospecies 13TU by sequencing being assigned to genospecies 3 by ASPE and one with concurrent genospecies 3 and genospecies 13TU signals.

^dNA, not applicable.

^eIsolates identified as not belonging to the 13 reference Acinetobacter species.